As shown in Figure 2A, high expression of YTHDF3 was linked to poor OS in the following cancers: BRCA (HR = 1.55, P = 0.007), CESC (HR = 2.79, P = 0.003), LGG (HR = 1.51, P = 0.016), UVM (HR = 3.26, P = 0.002), KICH (HR = 11.33, P = 0.004), PAAD (HR = 1.61, P = 0.022), SARC (HR = 1.81, P = 0.012), OV (HR = 1.36, P = 0.021), GBMLGG (Glioma) (HR = 1.57, P < 0.001), UCEC (HR = 1.94, P = 0.001), LIHC (HR = 1.50, P = 0.02), THCA (HR = 3.83, P = 0.012), and Lymphoid Neoplasm Diffuse Large B-cell Lymphoma (DLBC) (HR = 4.71, P = 0.022) within the TCGA project. Here, YTHDF3 is linked to central nervous system cancer.